Mankind Pharma has entered a strategic partnership with Denovo Sciences to enhance the drug discovery process through artificial intelligence.
The collaboration aims to streamline research efforts, focusing on three main objectives: shortening early drug discovery timelines, enhancing the quality of lead candidates, and advancing only those candidates with the highest potential for development. By leveraging AI technology, the partners hope to minimize resources spent on less viable candidates, thereby increasing efficiency in the drug development pipeline.
Combining Mankind Pharma's robust research and development capabilities with Denovo Sciences' advanced AI platform, the partnership will implement a "human-in-the-loop" approach. This model allows AI to generate and assess molecular candidates, while scientific experts oversee and refine the outcomes throughout the process.
The initiative is expected to lead to faster discovery cycles and improved candidate selection, ultimately facilitating the delivery of innovative and accessible therapies to patients. As Mankind Pharma's COO Arjun Juneja noted, this collaboration represents a significant investment in R&D that aligns with the company's mission to make drug discovery more efficient and precise, addressing the inherent uncertainties of the process.
Denovo Sciences' CEO Hovakim Zakaryan emphasized that the partnership is well-aligned with their platform's capabilities, which are designed to complement experienced drug discovery teams. This collaboration underscores the potential of AI in transforming the early stages of drug discovery, where informed decisions can significantly reduce development time.